All > Alzheimer Disease > Alzheimers Disease

[11C]PBR28 and[18F]NOS for Alzheimer Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Alzheimer Disease+1 More
[11C]PBR28 and[18F]NOS - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is being done to learn more about inflammation in the brain using PET/CT imaging in people with Alzheimer's Disease/Mild Cognitive Impairment or healthy controls.

Eligible Conditions
  • Alzheimer Disease
  • Healthy Subjects (HS)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
CSL889
1
Oxandrolone
1
NGM120

Study Objectives

3 Primary · 3 Secondary · Reporting Duration: 3 years

3 years
Comparing the patterns of [11C]PBR28 brain uptake with patterns of cerebral amyloidosis and neurodegeneration using PET/CT
Brain
Comparing the patterns of [18F]NOS brain uptake with patterns of cerebral amyloidosis and neurodegeneration using PET/CT
Understanding the uptake of [11C]PBR28 in the human brain in AD/MCI and Healthy Controls with a specific genetic polymorphism
Brain
understanding the uptake of [18F]NOS in the human brain in AD/MCI and Healthy Controls and compare to same-day [11C]PBR28 uptake using PET/CT scan

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
CSL889
1
Oxandrolone
1
NGM120

Trial Design

4 Treatment Groups

AD/MCI or HC with Genetic Polymorphism
1 of 4
AD/MCI or HC
1 of 4
patient with Alzheimer disease
1 of 4
Healthy volunteer
1 of 4

Experimental Treatment

20 Total Participants · 4 Treatment Groups

Primary Treatment: [11C]PBR28 and[18F]NOS · No Placebo Group · Phase < 1

AD/MCI or HC with Genetic Polymorphism
Drug
Experimental Group · 1 Intervention: [11C]PBR28 · Intervention Types: Drug
AD/MCI or HC
Drug
Experimental Group · 1 Intervention: [18F]NOS · Intervention Types: Drug
patient with Alzheimer disease
Drug
Experimental Group · 1 Intervention: [11C]PBR28 and[18F]NOS · Intervention Types: Drug
Healthy volunteer
Drug
Experimental Group · 1 Intervention: [11C]PBR28 and[18F]NOS · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 3 years

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor
1,822 Previous Clinical Trials
41,116,203 Total Patients Enrolled
17 Trials studying Alzheimer Disease
3,790 Patients Enrolled for Alzheimer Disease

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a mini-mental status exam score of 14-27 per ADC database.
You have a positive pregnancy test if you are male or female.
You must be informed of the investigational nature of this study and be willing to participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 26th, 2021

Last Reviewed: November 6th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References

Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top